[PDF] snmjournals.orgFree from Publisher

Somatostatin receptor–targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis

C Mirian, AK Duun-Henriksen, A Maier… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Somatostatin receptor (SSTR)–targeted peptide receptor radionuclide therapy (PRRT)
represents a promising approach for treatment-refractory meningiomas. Methods: We …
Save Cite Cited by 47 Related articles All 10 versions
[HTML] mdpi.com

[HTML][HTML] Somatostatin receptor theranostics for refractory meningiomas

B Salgues, T Graillon, T Horowitz, O Chinot… - Current …, 2022 - mdpi.com
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT)
represents a promising approach for treatment-refractory meningiomas progressing after …
Save Cite Cited by 13 Related articles All 8 versions Cached
[HTML] sciencedirect.com

[HTML][HTML] Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic …

PE Hartrampf, H Hänscheid, O Kertels… - Clinical and translational …, 2020 - Elsevier
Background The combination of somatostatin receptor-directed peptide receptor
radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might …
Save Cite Cited by 26 Related articles All 6 versions
[HTML] springer.comFull View

[HTML][HTML] Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

MC Kreissl, H Hänscheid, M Löhr, FA Verburg… - Radiation …, 2012 - Springer
Background External beam radiotherapy (EBRT) is the treatment of choice for irresectable
meningioma. Due to the strong expression of somatostatin receptors, peptide receptor …
Save Cite Cited by 81 Related articles All 13 versions
[HTML] oup.com

Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake

K Seystahl, V Stoecklein, U Schüller, E Rushing… - Neuro …, 2016 - academic.oup.com
Background The prognosis of patients with progressive meningioma after failure of surgery
and radiotherapy is poor. Methods We retrospectively evaluated the safety and efficacy of …
Save Cite Cited by 125 Related articles All 10 versions
[PDF] snmjournals.orgFree from Publisher

Somatostatin receptor–targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical …

N Marincek, P Radojewski, RA Dumont… - Journal of Nuclear …, 2015 - Soc Nuclear Med
Meningiomas express members of the somatostatin receptor family. The present study
assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in …
Save Cite Cited by 77 Related articles All 9 versions
[PDF] academia.edu

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

M Bartolomei, L Bodei, C De Cicco, CM Grana… - European journal of …, 2009 - Springer
Purpose Meningiomas are generally benign and in most cases surgery is curative. However,
for high-grade histotypes or partially resected tumours, recurrence is fairly common. External …
Save Cite Cited by 139 Related articles All 13 versions
[HTML] mdpi.com

[HTML][HTML] Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas: a systematic review of the literature

L Filippi, I Palumbo, O Bagni, O Schillaci, C Aristei… - Diagnostics, 2022 - mdpi.com
The aims of the present systematic review are to:(1) assess the diagnostic performance of
somatostatin receptor (SSR) targeted positron emission tomography (PET) with different …
Save Cite Cited by 9 Related articles All 9 versions Cached

Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma

NS Minczeles, EM Bos, RC de Leeuw, JM Kros… - European Journal of …, 2023 - Springer
Purpose There is no evidence-based systemic therapy for patients with progressive
meningiomas for whom surgery or external radiotherapy is no longer an option. In this study …
Save Cite Cited by 10 Related articles All 6 versions
[HTML] nih.gov

Hormone therapies in meningioma-where are we?

DF Miyagishima, J Moliterno, E Claus… - Journal of neuro-oncology, 2023 - Springer
Introduction Meningiomas are associated with several gonadal steroid hormone-related risk
factors and demonstrate a predominance in females. These associations led to …
Save Cite Cited by 10 Related articles All 6 versions